Equities

Imricor Medical Systems Inc

IMR:ASX

Imricor Medical Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.825
  • Today's Change0.015 / 1.85%
  • Shares traded117.10k
  • 1 Year change+41.99%
  • Beta0.8508
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Imricor Medical Systems, Inc. is a developer of magnetic resonance imaging (MRI)-compatible medical devices, which is used to carry out real-time interventional Cardiac Magnetic Resonance Imaging (iCMR) cardiac ablation procedures. The Company is engaged in designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Its products include Vision-mitral regurgitation (MR) Ablation Catheter, Advantage-MR electrophysiology (EP) Recorder/Stimulator and Vision-MR Dispersive Electrode. The Vision-MR Ablation Catheter is designed to work under real-time MRI guidance. Advantage-MR EP Recorder/Stimulator System provides technology that allows physicians to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The Company sells its products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.

  • Revenue in AUD (TTM)1.28m
  • Net income in AUD-31.41m
  • Incorporated2006
  • Employees--
  • Location
    Imricor Medical Systems Inc400 GATEWAY BLVDBURNSVILLE 55337-2559United StatesUSA
  • Phone+1 (952) 818-8402
  • Websitehttps://imricor.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Respiri Ltd1.04m-7.13m117.48m2.00--39.57--113.12-0.007-0.0070.0010.00230.22160.0026.91---152.14-153.06-384.52-255.3469.98---686.48-617.730.3744-108.650.0423--56.850.1379-23.44------
SDI Ltd111.21m10.42m127.78m300.0012.261.368.751.150.08770.08770.93560.79060.81181.555.51--7.617.139.328.4062.0859.869.378.191.408.010.208746.683.116.9247.697.2911.964.72
EchoIQ Ltd44.50k-5.41m132.42m----17.87--2,975.67-0.0109-0.01090.000090.01260.0048--0.1208---58.04-65.22-76.45-83.27-----12,155.39-1,722.30----0.00---58.54-44.2334.56------
Optiscan Imaging Ltd1.16m-6.06m142.01m8.00--10.24--122.89-0.0074-0.00740.00140.01660.11380.30620.9086---59.70-49.52-70.78-58.8454.4616.53-524.45-312.657.45--0.0157---31.221.91-39.27--80.89--
Orthocell Ltd6.76m-7.18m149.45m----28.86--22.09-0.0356-0.03560.03350.02170.24061.479.37---25.55-28.99-30.96-34.0275.9571.10-106.16-242.964.11--0.1321--32.7947.88-14.93--20.63--
Cyclopharm Limited29.04m-9.32m150.59m87.00--3.17--5.19-0.0976-0.09760.30660.42780.51211.114.01333,756.60-16.43-12.60-19.97-14.9464.7770.20-32.08-25.473.42-37.570.1049--11.2215.5028.90---7.83-12.94
Genetic Signatures Ltd14.27m-17.86m156.54m----2.43--10.97-0.1124-0.11240.08640.28380.24531.023.20---30.70-11.57-34.00-12.6944.5655.89-125.15-25.418.76-509.340.0196---35.2914.72-27.11--50.98--
Medadvisor Ltd122.11m792.13k165.39m100.00197.373.2033.161.350.00150.00150.22280.09371.25--11.12--0.8137-15.721.37-24.6060.8159.350.6487-15.38--1.520.1964--24.6467.75107.01--77.57--
EMvision Medical Devices Ltd11.56m-2.73m165.47m----8.93--14.31-0.033-0.0330.14370.21680.6515-------15.38-47.89-20.97-59.47-----23.61-100.24---16.560.1354--62.9959.0629.48------
Anteris Technologies Ltd7.14m-87.90m190.26m1.00--30.46--26.65-5.04-5.040.41220.29550.23613.235.01---304.00-120.86-529.47-189.2768.4366.40-1,287.57-316.850.9233-132.480.3869--4.48-22.85-51.86--42.27--
4DMedical Ltd3.75m-35.98m199.11m----2.81--53.04-0.0972-0.09720.01010.17280.03530.28570.5844---33.79-39.81-41.36-50.9093.6967.64-958.34-1,941.161.74--0.0673--422.4640.12-14.36---1.77--
Aroa Biosurgery Ltd62.61m-9.63m217.29m261.00--2.52--3.47-0.028-0.0280.18210.250.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Imricor Medical Systems Inc1.28m-31.41m218.84m--------171.29-0.1842-0.18420.0073-0.04920.10410.85013.78---255.91-93.47-387.91-106.30-110.81-134.71-2,458.30-2,462.890.799-4.554.73---24.56-9.29-30.36---10.82--
Data as of Nov 18 2024. Currency figures normalised to Imricor Medical Systems Inc's reporting currency: Australian Dollar AUD

Institutional shareholders

0.89%Per cent of shares held by top holders
HolderShares% Held
Investors Mutual Ltd.as of 31 Oct 20242.39m0.89%
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.